<DOC>
	<DOCNO>NCT00629863</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , endoscopic ultrasound , may help doctor learn extent stomach cancer esophageal cancer . PURPOSE : This randomized clinical trial study well endoscopic ultrasound work diagnose cancer patient localize stomach cancer esophageal cancer .</brief_summary>
	<brief_title>Endoscopic Ultrasound Diagnosing Cancer Patients With Localized Stomach Cancer Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine additional effect endoscopic ultrasound ( EUS ) stag compare standard stag algorithm selection treatment patient gastric esophageal cancer ( GOC ) , include number patient treat surgically , multimodality therapy , non-surgical mean . - To estimate effect EUS stag outcome care patient . - To assess cost-effectiveness EUS comparing improvement patient outcome additional cost procedure . - To estimate proportion patient GOC benefit EUS therefore determine need EUS facility within population . OUTLINE : This multicenter study . Patients stratify accord tumor location ( gastric v esophageal v gastroesophageal junction ) participate center . All patient undergo standard stag method . Patients localized tumor randomize undergo either endoscopic ultrasound ( EUS ) staging . Both group receive treatment follow , depend type tumor : - Mucosal tumor : Patients undergo endoscopic mucosal resection argon-beam ablation surround mucosa . - Resectable tumor : Patients undergo surgery neoadjuvant chemotherapy comprise cisplatin fluorouracil . - Advanced localized disease without possibility complete resection : Patients receive chemoradiotherapy chemotherapy alone depend upon site . Patients gastric cancer may undergo palliative surgery . Quality life assess 1 , 3 , 6 , 12 , 18 , 24 month use questionnaire , include EuroQol EQ-5D , EORTC core module QLQ-C30 , EORTC esophageal module QLQ-OES24 , EORTC gastric module QLQ-STO22 . After completion study treatment , patient follow every 3 month minimum 1 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis gastric esophageal cancer Localized disease No metastatic disease PATIENT CHARACTERISTICS : WHO performance status 02 American Society Anesthesiologists grade 1 ( physiological disturbance ) 2 ( minor wellcompensated physiological impairment ) Must fit surgery chemotherapy PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>